Skip to main content
Nexmmune, Inc.Portfolio

Preliminary Results from NexImmune’s Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition

By December 7, 2020March 9th, 2021No Comments